Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5484MR)

This product GTTS-WQ5484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5484MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6027MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11713MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ10272MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ3028MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6444MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ886MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ9755MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ2452MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 157
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW